Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2018 16:10 ET | Source: Novartis Pharma AG

Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma

Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical...
April 30, 2018 16:05 ET | Source: Novartis Pharma AG

New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval

Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48 ...
April 25, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to...
April 20, 2018 01:15 ET | Source: Novartis Pharma AG

New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients

Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis...
April 19, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer

Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1,...
April 19, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werden

Der Nettoumsatz steigt um 4% (kWk[1], +10% USD), vor allem dank folgender Beiträge: Entresto wächst um 126% (kWk) auf USD 200 Millionen, da es weltweit vermehrt eingesetzt wird Cosentyx legt um...
April 19, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments

Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto, qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le...
April 19, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong...
April 18, 2018 16:01 ET | Source: Novartis Pharma AG

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated...
April 17, 2018 16:00 ET | Source: Novartis Pharma AG

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

The LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials ...